T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
Status:
Active, not recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
This phase I/Ib trial studies the side effects and best dose of utomilumab and how well it
works with CD8-positive T-lymphocyte (T-cell infusion) and aldesleukin in treating patients
with ovarian cancer that has come back. Aldesleukin may stimulate white blood cells to kill
ovarian cancer cells. Giving white blood cells (T-cells) that have been activated by a
vaccine with aldesleukin may kill more tumor cells. Immunotherapy with utomilumab, may induce
changes in body's immune system and may interfere with the ability of tumor cells to grow and
spread. Giving T-cell infusion with aldesleukin and utomilumab may work better in treating
patients with ovarian cancer.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Immatics US, Inc. National Cancer Institute (NCI) Pfizer
Treatments:
Aldesleukin Antibodies, Monoclonal Cyclophosphamide Immunoglobulin G Interleukin-2